
    
      Design: This will be a prospective, randomized, multicenter, non-blinded phase III A study.

      Dosages: Arm A Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan
      1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d Arm B Topotecan 0.75 mg/m2/d i.v. on Days 1- 3
      in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d Duration of Therapy: Each
      patient will participate in the study until a maximum of six cycles have been completed, or
      until there is evidence of disease progression, or until toxicity prevents further therapy.
      Patients with continued response or stable disease may continue to participate in the study
      for an additional 3 cycles beyond the original 6 cycles with consent of the Study Director,
      but this must be documented in the CRF.
    
  